CME Group CME Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 65.6%+0.6pp | 64.9%+0.7pp | 65%+1.3pp | 65.3%+2.5pp | 64.9%+3.0pp | |
| Net margin | 63.6%+5.9pp | 62.5%+4.9pp | 58.8%+1.5pp | 58.4%+1.5pp | 57.7%+0.8pp | |
| Returns | ||||||
| Return on equity | 16%+2.6pp | 14.8%+1.5pp | 13.3%+1.0pp | 13.6%+1.7pp | 13.4%+1.7pp | |
| Return on invested capital | 15.4%+1.6pp | 15.2%+1.0pp | 14%+1.1pp | 14.2%+2.0pp | 13.8%+2.1pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 1×0.0× | 1×0.0× | 1×0.0× | 1×0.0× | 1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | 0.3×-0.3× | -0.2×-0.4× | 0.3×-0.1× | 0.4×-0.1× | 0.6×-0.1× | |
| Per Share | ||||||
| Book value per share | $73.29-2.3% | $79.73+8.4% | $78.21-0.2% | $76.98+0.2% | $75.04-0.6% | |
| Valuation | ||||||
| Market capitalization | $86.61B-14.9% | $98.47B+17.7% | $97.37B+22.5% | $97.79B+38.1% | $95.61B+23.3% | |
| Price / earnings | 20.2×-6.9× | 24.2×+0.4× | 25.9×+2.9× | 26×+4.5× | 26.4×+2.1× | |
| Price / sales | 12.8×-3.0× | 15.1×+1.5× | 15.2×+2.1× | 15.2×+3.0× | 15.2×+1.4× | |
| Price / book | 3.3×-0.4× | 3.4×+0.3× | 3.5×+0.6× | 3.5×+1.0× | 3.5×+0.7× | |
| EV / EBITDA | 19.1×-4.8× | 22.6×+1.6× | 23.1×+2.7× | 23.1×+3.7× | 23.4×+1.2× | |
| Dividend yield | 4.7%+0.9pp | 4%-0.3pp | 4%-0.5pp | 3.9%-1.1pp | 4%-0.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CME Group's ratios come from?
- Every ratio is computed from CME Group's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
